Comment on "Dexamethasone-sparing on days 2–4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)"

Luigi Celio,Andrea Antonuzzo,Matti S. Aapro

DOI: https://doi.org/10.1038/s41416-024-02611-z

IF: 9.075

2024-02-27

British Journal of Cancer

Abstract:Minatogawa et al. [1] should be commended for conducting this important trial. Antiemetic guidelines devised from the major international organizations recommend now olanzapine as a fixed part of a four-drug prophylactic regimen in the setting of highly emetogenic chemotherapy (HEC) [2, 3]. In light of this, it is clinically relevant that a four-drug regimen containing olanzapine, palonosetron, a neurokinin-1 receptor antagonist, and dexamethasone (DEX) single-dose was shown to be non-inferior to the guideline-recommended reference regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by cisplatin-based HEC. Also, in the SPARED trial both patients' global health status scores and the incidence of severe nausea were not worsened by DEX sparing beyond day 1. However, the authors failed to take into account the available evidence on the DEX sparing strategy in the cisplatin setting when interpreting the clinical implications of the study results. Despite the SPARED trial met its primary objective to demonstrate non-inferiority of the DEX-sparing arm in terms of complete response (CR) during the delayed phase, the authors did not confirm their study hypothesis that olanzapine 5 mg could substitute for DEX on days 2–4 to prevent delayed CINV following cisplatin. This position relies on the finding that DEX sparing beyond day 1 caused a significant increase in mild to moderate nausea and appetite loss [1]. It is interesting to note that a prior non-inferiority study (LUNG-NEPA trial) showed comparable antiemetic control during the 5 days post-chemotherapy with a three-drug regimen of NEPA (a fixed-dose combination of netupitant and palonosetron) plus DEX single-dose versus the standard reference treatment with 4-day DEX in the setting of high-dose (≥70 mg/m 2 ) cisplatin [4]. Although olanzapine was not used, efficacy results in the DEX-sparing arm are comparable to those seen in the SPARED trial not only in terms of CR rates (primary endpoint) but also rates of patients free of nausea or vomiting. While the patient population is similar between the two studies according to sex and age, only 80% of patients in the SPARED trial received cisplatin at a dose of 70 mg/m 2 or greater. Since olanzapine 5 mg combined with palonosetron, aprepitant, and multiple-day DEX was shown to be better than placebo plus the same standard regimen in patients undergoing cisplatin [5], it is important to underline that we are still lacking of evidence from an adequately powered trial comparing 5 mg with 10 mg olanzapine in the CINV setting [6]. Therefore, there is a question whether olanzapine 5 mg can provide full benefit in improving control of cisplatin-induced nausea when the drug is added to a standard antiemetic regimen with DEX sparing on days 2–4. In the SPARED trial, the results of secondary endpoints suggest that the ability to improve nausea control may be jeopardized when olanzapine 5 mg is administered in combination with the DEX-sparing strategy.

oncology